Posted by Michael Wonder on 12 Mar 2026
ARTHEx Biotech granted FDA fast track designation for ATX-01 for the treatment of myotonic dystrophy type 1
11 March 2026 - ARTHEx Biotech today announced that the US FDA has granted fast track designation to ATX-01 for the treatment of myotonic dystrophy type 1.
ATX-01 is ARTHEx's investigational RNA therapeutic designed to address the underlying genetic cause of myotonic dystrophy type 1, a highly disabling neuromuscular disorder with no known cure.
